FDA and FTC hold public workshop to better US biosimilar landscape

On 09 March 2020, the FDA and FTC held a public workshop to further their efforts in creating a better biosimilar landscape in the US. The Centre for Biosimilars reported that topics discussed at the conference included the damage caused by false and misleading statements and anti-competitive behaviour, and the regulatory impediments for launching biosimilars.